<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04898075</url>
  </required_header>
  <id_info>
    <org_study_id>2000028718</org_study_id>
    <secondary_id>20YVNR35460041</secondary_id>
    <nct_id>NCT04898075</nct_id>
  </id_info>
  <brief_title>Quit Nicotine: E-Cig Cessation Intervention</brief_title>
  <official_title>Quit Nicotine: E-Cig Cessation Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if a new intervention helps teenagers who vape&#xD;
      nicotine quit vaping. The program involves two parts: giving rewards (also called contingency&#xD;
      management [CM]) and online video counseling (also called cognitive behavioral therapy&#xD;
      [CBT]).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible participants will participate in a 4-week long Remote Contingency Management (Remote&#xD;
      CM) intervention that involves the delivery of CM procedures using tablets, weekly vaping&#xD;
      cessation CBT sessions, and follow-up appointments at 1, 3, 6, and 12 months.&#xD;
&#xD;
      Aim 1. To examine the feasibility, acceptability, and efficacy of web-based, remote&#xD;
      Contingency Management (CM) for nicotine abstinence plus individualized Cognitive Behavioral&#xD;
      Therapy (CBT) among youth e-cigarette (e-cig) users. High school students 13-19 years old who&#xD;
      are regular e-cig users who want to quit (N=100) will be randomized to the Active group (CM&#xD;
      for nicotine abstinence; reinforcement for negative saliva nicotine/cotinine; n=50) or&#xD;
      Control group (reinforcement for providing saliva nicotine; n=50) for 4 weeks. Both groups&#xD;
      will receive weekly CBT during this time (2 sessions prior to quitting, 4 weekly sessions&#xD;
      after quitting). The investigators expect the Active group to have better treatment outcomes&#xD;
      (7-day point prevalence abstinence at end-of-treatment [EOT] and follow ups [1, 3, 6, and 12-&#xD;
      months]) than the Control group.&#xD;
&#xD;
      Aim 2. To examine the relationship between e-cig use characteristics, dependence, e-cig&#xD;
      withdrawal, and treatment outcome/abstinence. It is anticipated that using higher nicotine&#xD;
      concentrations; using a greater total number of flavors; vaping frequently or endorsing&#xD;
      habitual use; and reporting fewer prior quit attempts will be associated with experiencing&#xD;
      more severe dependence and e-cig withdrawal. In turn, researchers expect that experiencing&#xD;
      more severe e-cig dependence before quitting and/or more severe withdrawal following the quit&#xD;
      date will predict treatment failure (e.g., failure to achieve abstinence, a longer duration&#xD;
      until abstinence is achieved, higher cotinine levels)&#xD;
&#xD;
      Aim 3. To test for changes in neurocognitive functioning in adolescent e-cig users across&#xD;
      treatment for e- cig cessation. In this study, the Adolescent Brain and Cognitive Development&#xD;
      study neurocognitive battery will be utilized. This will be administered at baseline and end&#xD;
      of treatment to all participants (N=100). It is anticipated that youth e-cig users will show&#xD;
      improvements in neurocognitive task performance (e.g., working memory, attention) from&#xD;
      baseline to end of treatment. It is also predicted that improvements in neurocognitive task&#xD;
      performance will be related to abstinence from e-cigs during treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 7-day point prevalence abstinence</measure>
    <time_frame>1, 3, 6, and 12 month</time_frame>
    <description>Self reported of no e-cig usage during the 7 days prior and confirmed negativity with cotinine levels of 30ng/mL (Alere iScreen OFD Cotinine Saliva Test; Countrywide Testing).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>E-Cig Use</condition>
  <arm_group>
    <arm_group_label>Remote Contingency Management (CM) for nicotine abstinence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be paid increasing amounts of payment for each negative saliva cotinine test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be paid for providing saliva nicotine test, regardless of whether the test is positive or negative.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Remote Contingency Management (CM) for nicotine abstinence</intervention_name>
    <description>Participants will be paid increasing amounts of payment for each negative saliva cotinine test.</description>
    <arm_group_label>Remote Contingency Management (CM) for nicotine abstinence</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Participants will be paid for providing saliva nicotine test, regardless of whether the test is positive or negative.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  High school students between ages 13-19 years (plus 5 high school aged pilot&#xD;
             participants)&#xD;
&#xD;
          -  Able to read and write&#xD;
&#xD;
          -  Regular e-cig users using nicotine (primary e-cig users with or without other tobacco&#xD;
             use who report using e-cigs at least 4 days/week and have urine cotinine levels â‰¥200&#xD;
             ng/ml as determined by 1 Panel Quickscreen Cotinine/Nicotine Test Dipcard, COT200;&#xD;
             Countrywide Testing) who want to quit. A repeat urine may be tested with the 200ng/ml&#xD;
             dip test if subject reports levels of vaping that may be consistent with higher levels&#xD;
             of cotinine.&#xD;
&#xD;
          -  Does not meeting criteria for dependence on other psychoactive substances, psychosis,&#xD;
             major depression or panic disorder based on psychological evaluation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently enrolled in, or planning to enroll in any other behavioral or&#xD;
             pharmacological treatments for cessation of nicotine or vaping.&#xD;
&#xD;
          -  Current criteria for Substance Use Dependence (SUD) on other psychoactive substances.&#xD;
             Endorsement of mild Cannabis Use Disorder will be allowed, due to the fact than many&#xD;
             nicotine users may also be vaping cannabis&#xD;
&#xD;
          -  Current diagnosis of psychosis or evidence of significant homicidal/suicidal risk.&#xD;
&#xD;
          -  Current diagnosis of a significant mental health disorder that is not being treated by&#xD;
             a mental health practitioner with either behavioral and/or pharmacological&#xD;
             interventions.&#xD;
&#xD;
          -  Regular use of any psychoactive drugs including anxiolytics and antidepressants unless&#xD;
             the adolescent has been taking the medication consistently for 2 months, the&#xD;
             medication is currently being monitored by a physician, and the condition for which&#xD;
             the medication is taken is considered to be stable.&#xD;
&#xD;
          -  Females who report being pregnant or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suchitra Krishnan-Sarin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suchitra Krishnan-Sarin, PhD</last_name>
    <phone>(203) 974-7595</phone>
    <email>suchitra.krishnan-sarin@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Liss, BS</last_name>
    <phone>(203) 974-7555</phone>
    <email>thomas.liss@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Liss</last_name>
      <phone>203-974-7555</phone>
      <email>thomas.liss@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heather LaVallee</last_name>
      <phone>203-974-7373</phone>
      <email>heather.sarnataro@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Suchitra Krishnan-Sarin, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contingency management</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

